ImageneBio (IMA) Asset Utilization Ratio (2021 - 2025)

ImageneBio (IMA) posted Asset Utilization Ratio of 0.08 for Q1 2025, up 74.61% sequentially from 0.05 in Q3 2024.

ImageneBio (IMA) Asset Utilization Ratio (2021 - 2025) Analysis & Trends

ImageneBio has reported Asset Utilization Ratio for 5 years, with the latest figure at 0.08 in Q1 2025.

Quarterly Asset Utilization Ratio changed N/A year-over-year to 0.08 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was 0.08 (changed N/A YoY) and the FY2023 annual result came in at 0.05, down 32.37% from the prior year.
Asset Utilization Ratio rose to 0.08 in Q1 2025 per IMA's latest filing, from 0.05 in the prior quarter.
Over five years, Asset Utilization Ratio peaked at 0.15 in Q3 2022 and troughed at 0.03 in Q2 2021.
A 5-year average of 0.09 and a median of 0.08 in 2022 frame the typical range for Asset Utilization Ratio.
The sharpest annual moves came in 2022 and 2023: Asset Utilization Ratio soared 277.43% in 2022, then tumbled 52.36% in 2023.
Over 5 years, Asset Utilization Ratio stood at 0.12 in 2021, then dropped by 29.19% to 0.09 in 2022, then slumped by 47.78% to 0.04 in 2023, then grew by 6.63% to 0.05 in 2024, then jumped by 74.61% to 0.08 in 2025.
According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.08, 0.05, and 0.04 for Q1 2025, Q3 2024, and Q4 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	0.47
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	0.38
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	0.20
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	0.69
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	0.90
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	0.54
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.13
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	0.13
10	ImageneBio	48.60 Mn	-86.75 Mn	-	-

Download Data